Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

dactinomycin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Topoisomerase II inhibitor, RNA synthesis inhibitor

Related drugs:

‹

pirarubicin (1)

echinomycin (0)

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

mitoxantrone (16)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

pirarubicin (1)

echinomycin (0)

›

No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2	dactinomycin Sensitive: C2 – Inclusion Criteria dactinomycin Sensitive : C2
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4
IDH2 mutation	Glioma	IDH2 mutation	Glioma	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D	dactinomycin Sensitive: D – Preclinical dactinomycin Sensitive : D